Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.61 |
| ▸ | GRM5 | P41594 | 8/20 | 0.61 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099413 | 1.00 | CHRNA7 (0.61) | CHRNA7GRM5SMYD3KDM4EGAA | |
| SCHEMBL6102229 | 0.94 | GRM5 (0.63) | CHRNA7GRM5SMYD3KDM4EGAA | |
| SCHEMBL6100893 | 0.84 | CHRNA7 (0.58) | CHRNA7GRM5KMT2AKDM5AUSP30 | |
| SCHEMBL6100887 | 0.84 | CHRNA7 (0.58) | CHRNA7GRM5KMT2AKDM5AUSP30 | |
| SCHEMBL6098248 | 0.81 | CHRNA7 (0.69) | CHRNA7USP30 | |
| SCHEMBL6098256 | 0.81 | CHRNA7 (0.69) | CHRNA7USP30 | |
| SCHEMBL4795803 | 0.80 | CHRNA7 (0.75) | CHRNA7KMT2A | |
| SCHEMBL6100979 | 0.79 | CHRNA7 (0.59) | CHRNA7GRM5SMYD3USP30 | |
| SCHEMBL6101110 | 0.79 | CHRNA7 (0.61) | CHRNA7GRM5SMYD3USP30 | |
| SCHEMBL6101120 | 0.79 | CHRNA7 (0.61) | CHRNA7GRM5SMYD3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | claimed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | CHRNA7 1836/4885GRM5 1965/4885SMYD3 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.